Follow
https://www.bmj.com/content/372/bmj.n627
"EMA scientists worried about “truncated and modified mRNA species present in the finished product.”" "Commercial manufacturing was not producing vaccines to the specifications expected, and regulators were unsure of the implications."
So not only do we have a problem with failure to report side effects, as AstraZeneca admitted(1). But the type of side effects could vary on a batch-to-batch basis, making statistics difficult to collect.
@pete makes no sense that the government agencies keep information on target purity confidential? They are not branches of big pharma companies, at least not officially
I've been saying for literally months that manufacturing was a potential problem, because what was tested may not be what was actually produced due to the challenges in scaling up manufacturing. Sure enough, turns out the regulators shared my concerns.